Enovis Stock Price, News & Analysis (NYSE:ENOV) $48.74 -2.48 (-4.84%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$48.73▼$50.5850-Day Range$43.67▼$52.7352-Week Range$43.04▼$66.71Volume688,139 shsAverage Volume470,518 shsMarket Capitalization$2.66 billionP/E RatioN/ADividend YieldN/APrice Target$67.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Enovis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside39.2% Upside$67.83 Price TargetShort InterestBearish7.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.15Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth14.29%From $2.38 to $2.72 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector411th out of 948 stocksSurgical Appliances & Supplies Industry11th out of 18 stocks 3.5 Analyst's Opinion Consensus RatingEnovis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $67.83, Enovis has a forecasted upside of 39.2% from its current price of $48.74.Amount of Analyst CoverageEnovis has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.50% of the float of Enovis has been sold short.Short Interest Ratio / Days to CoverEnovis has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Enovis has recently increased by 3.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEnovis does not currently pay a dividend.Dividend GrowthEnovis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENOV. Previous Next 3.4 News and Social Media Coverage News SentimentEnovis has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Enovis this week, compared to 3 articles on an average week.Search Interest1 people have searched for ENOV on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Enovis to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enovis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of Enovis is held by insiders.Percentage Held by Institutions98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Enovis are expected to grow by 14.29% in the coming year, from $2.38 to $2.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enovis is -35.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enovis is -35.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnovis has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enovis Stock (NYSE:ENOV)Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufacture and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.Read More ENOV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENOV Stock News HeadlinesDecember 6, 2023 | americanbankingnews.comEnovis Co. (NYSE:ENOV) Receives Average Rating of "Buy" from AnalystsDecember 5, 2023 | finance.yahoo.comEnovis Announces Business Segment Leadership Transition PlanDecember 6, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 29, 2023 | finance.yahoo.comHow Much Upside is Left in Enovis (ENOV)? Wall Street Analysts Think 38.3%November 16, 2023 | finance.yahoo.comEnovis to participate in the 6th Annual EverCore ISI HealthCONx ConferenceNovember 13, 2023 | finance.yahoo.comCan Enovis (ENOV) Climb 43.82% to Reach the Level Wall Street Analysts Expect?November 8, 2023 | markets.businessinsider.comAnalysts’ Top Technology Picks: Enovis (ENOV), Uber Technologies (UBER)November 8, 2023 | finance.yahoo.comEnovis Corporation (ENOV) Shares Consolidated Gains on Investor ConcernsDecember 6, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 8, 2023 | finance.yahoo.comEnovis Corporation (NYSE:ENOV) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | finanznachrichten.deEnovis Corporation: Enovis Announces Third Quarter 2023 Results and Raises Full-Year OutlookNovember 8, 2023 | finance.yahoo.comQ3 2023 Enovis Corp Earnings CallNovember 8, 2023 | finance.yahoo.comDoes Enovis (ENOV) Have a Long Runway for Continued Earnings Growth?November 7, 2023 | msn.comTegna Q3 Earnings Down As Revenues DeclineNovember 7, 2023 | msn.comEnovis Corporation Non-GAAP EPS of $0.56 beats by $0.02, revenue of $417.52M beats by $3.19MNovember 7, 2023 | finance.yahoo.comEnovis Corp (ENOV) Reports 9% Sales Growth in Q3 2023, Raises Full-Year OutlookNovember 7, 2023 | finance.yahoo.comEnovis (ENOV) Q3 Earnings and Revenues Beat EstimatesNovember 7, 2023 | finance.yahoo.comEnovis Announces Third Quarter 2023 Results and Raises Full-Year OutlookOctober 30, 2023 | finance.yahoo.comEnovis™ to Showcase New Surgical Innovations at AAHKS Annual MeetingOctober 29, 2023 | finance.yahoo.comThe past five years for Enovis (NYSE:ENOV) investors has not been profitableOctober 20, 2023 | msn.comRoth MKM starts Enovis at buy, cites revenue growth potentialOctober 20, 2023 | markets.businessinsider.com4 Analysts Have This to Say About EnovisOctober 20, 2023 | msn.comEnovis announces pricing of private offeringOctober 20, 2023 | finance.yahoo.comENOVIS CORPORATION ANNOUNCES PRICING OF PRIVATE OFFERING OF $400 MILLION OF 3.875% CONVERTIBLE SENIOR NOTES DUE 2028October 19, 2023 | benzinga.comWhy Enovis Stock Is Trading Lower TodayOctober 19, 2023 | benzinga.comEnovis Corporation Releases Preliminary Information About Its Performance for the Third Quarter 2023October 19, 2023 | markets.businessinsider.comEnovis To Offer $400 Mln Of Convertible Senior Notes In Private PlacementSee More Headlines Receive ENOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNYSE:ENOV CUSIPN/A CIK1420800 Webwww.enovis.com Phone302-252-9160Fax301-323-9001Employees6,800Year FoundedN/APrice Target and Rating Average Stock Price Target$67.83 High Stock Price Target$75.00 Low Stock Price Target$62.00 Potential Upside/Downside+39.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.37) Trailing P/E RatioN/A Forward P/E Ratio20.48 P/E GrowthN/ANet Income$-13,290,000.00 Net Margins-4.51% Pretax Margin-4.66% Return on Equity3.70% Return on Assets2.93% Debt Debt-to-Equity Ratio0.11 Current Ratio2.40 Quick Ratio1.08 Sales & Book Value Annual Sales$1.66 billion Price / Sales1.60 Cash Flow$6.06 per share Price / Cash Flow8.04 Book Value$63.71 per share Price / Book0.76Miscellaneous Outstanding Shares54,594,000Free Float51,810,000Market Cap$2.66 billion OptionableOptionable Beta1.98 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Matthew L. Trerotola (Age 56)CEO & Chairman Comp: $5.12MMr. Brady R. Shirley (Age 57)President, COO & Director Comp: $3.34MMs. Patricia A. Lang (Age 64)Senior VP & Chief Human Resources Officer Comp: $1.59MMr. Daniel A. Pryor (Age 55)Executive Vice President of Strategy & Business Development Comp: $2.08MMr. Phillip Benjamin Berry (Age 44)Senior VP & CFO Mr. John Kleckner (Age 46)VP, Controller & Chief Accounting Officer Derek LeckowVice President of Investor RelationsMr. Bradley J. Tandy (Age 64)Senior VP & General Counsel Katie SweetVice President of Corporate CommunicationBrian P. HaniganSecretaryMore ExecutivesKey CompetitorsAvanos MedicalNYSE:AVNSAmphastar PharmaceuticalsNASDAQ:AMPHOrganon & Co.NYSE:OGNFortreaNASDAQ:FTREStructure TherapeuticsNASDAQ:GPCRView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Sold 79,882 shares on 11/30/2023Ownership: 1.593%Comerica BankBought 53,404 shares on 11/21/2023Ownership: 0.098%Walleye Trading LLCBought 1,200 shares on 11/21/2023Ownership: 0.000%Walleye Capital LLCBought 900 shares on 11/21/2023Ownership: 0.000%Ironwood Investment Management LLCSold 314 shares on 11/16/2023Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions ENOV Stock Analysis - Frequently Asked Questions Should I buy or sell Enovis stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENOV shares. View ENOV analyst ratings or view top-rated stocks. What is Enovis' stock price target for 2024? 5 equities research analysts have issued twelve-month price targets for Enovis' shares. Their ENOV share price targets range from $62.00 to $75.00. On average, they expect the company's stock price to reach $67.83 in the next year. This suggests a possible upside of 39.2% from the stock's current price. View analysts price targets for ENOV or view top-rated stocks among Wall Street analysts. How have ENOV shares performed in 2023? Enovis' stock was trading at $53.52 at the beginning of the year. Since then, ENOV shares have decreased by 8.9% and is now trading at $48.7350. View the best growth stocks for 2023 here. Are investors shorting Enovis? Enovis saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 3,610,000 shares, an increase of 11.4% from the October 15th total of 3,240,000 shares. Based on an average daily volume of 553,400 shares, the days-to-cover ratio is currently 6.5 days. Approximately 7.3% of the company's shares are short sold. View Enovis' Short Interest. When is Enovis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our ENOV earnings forecast. How were Enovis' earnings last quarter? Enovis Co. (NYSE:ENOV) posted its earnings results on Tuesday, November, 7th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.02. The firm had revenue of $417.50 million for the quarter, compared to the consensus estimate of $414.89 million. Enovis had a positive trailing twelve-month return on equity of 3.70% and a negative net margin of 4.51%. Enovis's quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the company posted $0.59 EPS. What ETFs hold Enovis' stock? ETFs with the largest weight of Enovis (NYSE:ENOV) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap 400 Pure Value ETF (RFV) and Dimensional US Small Cap Value ETF (DFSV).iShares U.S. Medical Devices ETF (IHI). What guidance has Enovis issued on next quarter's earnings? Enovis issued an update on its FY23 earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of $2.30-2.40 for the period, compared to the consensus EPS estimate of $2.32. Who are Enovis' major shareholders? Enovis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Diamond Hill Capital Management Inc. (4.45%), DAVENPORT & Co LLC (3.06%), Channing Capital Management LLC (2.30%), Allspring Global Investments Holdings LLC (1.88%), American Century Companies Inc. (1.59%) and Principal Financial Group Inc. (1.53%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota. View institutional ownership trends. How do I buy shares of Enovis? Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:ENOV) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.